SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis ...Middle East

PR Newswire - News
The Data Safety Monitoring Board (DSMB) finds no safety concerns in the 50 mg and 100 mg dose cohorts Signs of efficacy against rheumatoid arthritis was observed. Thus, the number of patients changing from the severe to the moderate Clinical Disease Activity Index (CDAI) score was higher...

Read More Details
Finally We wish PressBee provided you with enough information of ( SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis )

Apple Storegoogle play

Also on site :